Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL.

PubWeight™: 0.82^‹?›

🔗 View Article (PMID 26578735)

Published in Ann Oncol on November 16, 2015

Authors

J N Graff¹, G Baciarello², A J Armstrong³, C S Higano⁴, P Iversen⁵, T W Flaig⁶, D Forer⁷, T Parli⁷, D Phung⁸, B Tombal⁹, T M Beer¹⁰, C N Sternberg²

Author Affiliations

1: Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland Division of Oncology, Portland VA Medical Center, Portland, USA graffj@ohsu.edu.
2: Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy.
3: Divisions of Medical Oncology and Urology, Duke University Medical Center and the Duke Cancer Institute, Durham.
4: Division of Medical Oncology, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, USA.
5: Copenhagen Prostate Cancer Center, Rigshospitalet, University of Copenhagen, København, Denmark.
6: Department of Medical Oncology, University of Colorado Cancer Center, Aurora.
7: Medivation, Inc., San Francisco, USA.
8: Astellas Pharma Global Development, Inc., Leiden, The Netherlands.
9: Department of Urology, Cliniques Universitaires Saint-Luc, Brussels, Belgium.
10: Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland.

Associated clinical trials:

A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer (PREVAIL) | NCT01212991

Articles citing this ↘

Impact of enzalutamide on patient-related outcomes in metastatic castration-resistant prostate cancer: current perspectives. Res Rep Urol (2016) 0.75

Metastatic castration-resistant prostate cancer in very elderly patients: challenges and solutions. Clin Interv Aging (2016) 0.75

Targeting the androgenic pathway in elderly patients with castration-resistant prostate cancer: A meta-analysis of randomized trials. Medicine (Baltimore) (2016) 0.75

Falls and Frailty in Prostate Cancer Survivors: Current, Past, and Never Users of Androgen Deprivation Therapy. J Am Geriatr Soc (2017) 0.75

Articles by these authors ⇆

Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol (2015) 2.99

Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials. Ann Oncol (2014) 1.75

Many men with castrate-sensitive metastatic prostate cancer should not receive chemotherapy. Ann Oncol (2015) 1.05

Metastatic renal cell cancer treatments. Drugs Today (Barc) (2003) 0.80

Muscle invasive and metastatic bladder cancer. Ann Oncol (2006) 0.79

Second-line treatment for metastatic clear cell renal cell cancer: experts' consensus algorithms. World J Urol (2016) 0.78

Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL. Prostate Cancer Prostatic Dis (2017) 0.75

A randomized, double blind, placebo controlled phase 2 study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapy. Ann Oncol (2017) 0.75